Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. develops innovative therapeutics for patients with critical diseases. The company focuses on advancing medical treatments for conditions such as infectious diseases and oncology. The company self-described as unlocking potential faster.

COM:CITIUSPHARMA

Citius Pharmaceuticals, Inc.

Last Close

0.17

21/11 21:00

Market Cap

134.75M

Beta: -

Volume Today

4.54M

Avg: -

People Not Available